Inhibition of Notch signaling in combination with paclitaxel reduces platinum-resistant ovarian tumor growth

Frontiers in Oncology

Volumn 4 JUL, Issue , 2014, Pages

  Groeneweg, Jolijn W ^a,b   DiGloria, Celeste M ^a   Yuan, Jing ^c   Richardson, William S ^a   Growdon, Whitfield B ^a,b   Sathyanarayanan, Sriram ^c   Foster, Rosemary ^a,b   Rueda, Bo R ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

chemoresistance; Notch; Ovarian cancer; Patient derived xenograft; Secretase inhibitor

Indexed keywords

CARBOPLATIN; GAMMA SECRETASE INHIBITOR; MRK 003; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; PACLITAXEL; PLATINUM; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOUSE; NONHUMAN; OVARY TUMOR; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; VERY ELDERLY;

EID: 84904663282     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00171     Document Type: Article

References (57)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin (2012) 62(1):10-29. doi:10.3322/caac.21149
2. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature (2011) 474(7353):609-15. doi:10.1038/nature10166
3. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2003) 21(17):3194-200. doi:10.1200/JCO.2003.02.153
4. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 354(1):34-43. doi:10.1056/NEJMoa052985
5. Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol (2011) 12(12):1169-74. doi:10.1016/S1470-2045(11)70123-1
6. Pinato DJ, Graham J, Gabra H, Sharma R. Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treat Rev (2013) 39(2):153-60. doi:10.1016/j.ctrv.2012.04.004
7. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene (2008) 27(38):5124-31. doi:10.1038/onc.2008.226
8. Chen J, Kesari S, Rooney C, Strack PR, Shen H, Wu L, et al. Inhibition of Notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer (2010) 1(8):822-35. doi:10.1177/1947601910383564
9. Mizuma M, Rasheed ZA, Yabuuchi S, Omura N, Campbell NR, de Wilde RF, et al. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol Cancer Ther (2012) 11(9):1999-2009. doi:10.1158/1535-7163.MCT-12-0017
10. Reedijk M. Notch signaling and breast cancer. Adv Exp Med Biol (2012) 727:241-57. doi:10.1007/978-1-4614-0899-4_18
11. Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther (2013) 139(2):95-110. doi:10.1016/j.pharmthera.2013.02.003
12. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell (2009) 137(2):216-33. doi:10.1016/j.cell.2009.03.045
13. Koch U, Lehal R, Radtke F. Stem cells living with a Notch. Development (2013) 140(4):689-704. doi:10.1242/dev.080614
14. Guruharsha KG, Kankel MW, Artavanis-Tsakonas S. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet (2012) 13(9):654-66. doi:10.1038/nrg3272
15. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell (2009) 16(5):633-47. doi:10.1016/j.devcel.2009.03.010
16. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer (2011) 11(5):338-51. doi:10.1038/nrc3035
17. Miele L, Golde T, Osborne B. Notch signaling in cancer. Curr Mol Med (2006) 6(8):905-18. doi:10.2174/156652406779010830
18. Guilmeau S. Notch signaling and intestinal cancer. Adv Exp Med Biol (2012) 727:272-88. doi:10.1007/978-1-4614-0899-4_21
19. Hu YY, Zheng MH, Zhang R, Liang YM, Han H. Notch signaling pathway and cancer metastasis. Adv Exp Med Biol (2012) 727:186-98. doi:10.1007/978-1-4614-0899-4_14
20. Speiser J, Foreman K, Drinka E, Godellas C, Perez C, Salhadar A, et al. Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer. Int J Surg Pathol (2012) 20(2):139-45. doi:10.1177/1066896911427035
21. South AP, Cho RJ, Aster JC. The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol (2012) 23(4):458-64. doi:10.1016/j.semcdb.2012.01.017
22. Rose SL, Kunnimalaiyaan M, Drenzek J, Seiler N. Notch 1 signaling is active in ovarian cancer. Gynecol Oncol (2010) 117(1):130-3. doi:10.1016/j.ygyno.2009.12.003
23. Wang M, Wang J, Wang L, Wu L, Xin X. Notch1 expression correlates with tumor differentiation status in ovarian carcinoma. Med Oncol (2010) 27(4):1329-35. doi:10.1007/s12032-009-9384-8
24. Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z, et al. Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 66(12):6312-8. doi:10.1158/0008-5472.CAN-05-3610
25. Choi JH, Park JT, Davidson B, Morin PJ, Shih IeM, Wang TL. Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res (2008) 68(14):5716-23. doi:10.1158/0008-5472.CAN-08-0001
26. Hopfer O, Zwahlen D, Fey MF, Aebi S. The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer (2005) 93(6):709-18. doi:10.1038/sj.bjc.6602719
27. Chen X, Thiaville MM, Chen L, Stoeck A, Xuan J, Gao M, et al. Defining Notch3 target genes in ovarian cancer. Cancer Res (2012) 72(9):2294-303. doi:10.1158/0008-5472.CAN-11-2181
28. Park JT, Chen X, Trope CG, Davidson B, Shih Ie M, Wang TL. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol (2010) 177(3):1087-94. doi:10.2353/ajpath.2010.100316
29. Jung SG, Kwon YD, Song JA, Back MJ, Lee SY, Lee C, et al. Prognostic significance of Notch 3 gene expression in ovarian serous carcinoma. Cancer Sci (2010) 101(9):1977-83. doi:10.1111/j.1349-7006.2010.01641.x
30. Oktem G, Sanci M, Bilir A, Yildirim Y, Kececi SD, Ayla S, et al. Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer. Int J Gynecol Cancer (2012) 22(1):23-9. doi:10.1097/IGC.0b013e31823228b2
31. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 68(11):4311-20. doi:10.1158/0008-5472.CAN-08-0364
32. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res (2012) 18(3):869-81. doi:10.1158/1078-0432.CCR-11-2188
33. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One (2012) 7(1):e29079. doi:10.1371/journal.pone.0029079
34. Lewis HD, Leveridge M, Strack PR, Haldon CD, O'Neil J, Kim H, et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of Notch signaling. Chem Biol (2007) 14(2):209-19. doi:10.1016/j.chembiol.2006.12.010
35. Egloff AM, Grandis JR. Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. Clin Cancer Res (2012) 18(19):5188-95. doi:10.1158/1078-0432.CCR-11-2258
36. Wang M, Wu L, Wang L, Xin X. Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780. Biochem Biophys Res Commun (2010) 393(1):144-9. doi:10.1016/j.bbrc.2010.01.103
37. Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, et al. Targeting the Notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res (2011) 17(17):5674-85. doi:10.1158/1078-0432.CCR-11-0432
38. Drenzek JG, Seiler NL, Jaskula-Sztul R, Rausch MM, Rose SL. Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines. Gynecol Oncol (2011) 122(2):396-401. doi:10.1016/j.ygyno.2011.04.027
39. McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A (2012) 109(43):E2939-48. doi:10.1073/pnas.1206400109
40. Osanyingbemi-Obidi J, Dobromilskaya I, Illei PB, Hann CL, Rudin CM. Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Mol Cancer Res (2011) 9(12):1746-54. doi:10.1158/1541-7786.MCR-11-0286
41. Ramakrishnan V, Ansell S, Haug J, Grote D, Kimlinger T, Stenson M, et al. MRK003, a gamma-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma. Leukemia (2012) 26(2):340-8. doi:10.1038/leu.2011.192
42. Kondratyev M, Kreso A, Hallett RM, Girgis-Gabardo A, Barcelon ME, Ilieva D, et al. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene (2012) 31(1):93-103. doi:10.1038/onc.2011.212
43. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP, et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res (2007) 67(17):8051-7. doi:10.1158/0008-5472.CAN-07-1022
44. McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL, et al. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS One (2011) 6(11):e28077. doi:10.1371/journal.pone.0028077
45. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 29(9):e45. doi:10.1093/nar/29.9.e45
46. Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, et al. Gauging Notch1 activation in cancer using immunohistochemistry. PLoS One (2013) 8(6):e67306. doi:10.1371/journal.pone.0067306
47. Park JT, Shih Ie M, Wang TL. Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res (2008) 68(21):8852-60. doi:10.1158/0008-5472.CAN-08-0517
48. Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, et al. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer. Am J Clin Pathol (2012) 138(4):535-44. doi:10.1309/AJCPKDLRQ8F3EWNS
49. Gupta N, Xu Z, El-Sehemy A, Steed H, Fu Y. Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells. Gynecol Oncol (2013) 130(1):200-6. doi:10.1016/j.ygyno.2013.03.019
50. Foster R, Buckanovich RJ, Rueda BR. Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett (2013) 338(1):147-57. doi:10.1016/j.canlet.2012.10.023
51. Schreck KC, Taylor P, Marchionni L, Gopalakrishnan V, Bar EE, Gaiano N, et al. The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res (2010) 16(24):6060-70. doi:10.1158/1078-0432.CCR-10-1624
52. Markman M, Reichman B, Hakes T, Jones W, Lewis JL Jr, Rubin S, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol (1991) 9(10):1801-5.
53. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol (1991) 9(3):389-93.
54. Takebe N, Nguyen D, Yang SX. Targeting Notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther (2013) 141(2):140-9. doi:10.1016/j.pharmthera.2013.09.005
55. Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol (2011) 29(26):3529-34. doi:10.1200/JCO.2011.35.7806
56. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol (2012) 30(19):2307-13. doi:10.1200/JCO.2011.39.1540
57. Avila JL, Kissil JL. Notch signaling in pancreatic cancer: oncogene or tumor suppressor? Trends Mol Med (2013) 19(5):320-7. doi:10.1016/j.molmed.2013.03.003